Financial Summary (All financials)
| In millions, except per share items | Mar-31-23 | Mar-31-22 | Mar-31-21 | Mar-31-20 |
| Revenues | 1,902.1 | 1,457.6 | 1,195.6 | 1,171.3 |
| Revenue growth | 30.5% | 21.9% | 2.1% | |
| Cost of goods sold | 1,615.2 | 1,310.6 | 963.6 | 958.4 |
| Gross profit | 287.0 | 147.0 | 232.0 | 212.9 |
| Gross margin | 15.1% | 10.1% | 19.4% | 18.2% |
| Selling, general and administrative | 96.9 | 66.9 | 60.4 | 55.4 |
| Research and development | 21.6 | 14.2 | 13.0 | 8.6 |
| EBITA | 169.7 | 74.4 | 173.5 | 148.9 |
| EBITA margin | 8.9% | 5.1% | 14.5% | 12.7% |
| Amortization of intangibles | 1.2 | 8.5 | 15.0 | |
| EBIT | 168.5 | 65.9 | 158.5 | 148.9 |
| EBIT margin | 8.9% | 4.5% | 13.3% | 12.7% |
| Pre-tax income | 169.1 | 65.1 | 158.0 | 148.9 |
| Income taxes | 47.8 | 14.2 | 33.7 | 30.7 |
| Tax rate | 28.2% | 21.8% | 21.3% | 20.6% |
| Net income | 121.3 | 50.9 | 124.3 | 118.3 |
| Net margin | 6.4% | 3.5% | 10.4% | 10.1% |
| |
| Diluted EPS | $0.83 | | | |
| Shares outstanding (diluted) | 145.9 | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|